Using altered peptide ligands derived from the ovalbumin OVA257–264 peptide, they showed that the duration of TCR–pMHC interactions (t1/2) regulated effector function and tumor-killing capacities of OT-1-specific CD8 T cells (80). This evidence concerns the gene CD8A and neoplasm.